Dr. Timothy Kieffer was appointed Aardvark's Chief Scientific Officer in May 2025. A globally recognized academic leader in diabetes mechanisms and translational medicine, he previously served as Chief Scientific Officer at ViaCyte, Inc. (acquired by Vertex Pharmaceuticals) and subsequently at Fractyl Health. Before industry, he led the Laboratory of Molecular and Cellular Medicine at the University of British Columbia, focusing on gene and cell therapy approaches to treat diabetes. Dr. Kieffer has co-authored more than 200 peer-reviewed publications and holds patents in the field. He received his Ph.D. in Physiology from the University of British Columbia and completed post-doctoral training at Massachusetts General Hospital and Harvard Medical School.